How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,908 results for

Psoriasis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Psoriasis in Solid Organ Transplant Patients: Best Practice Recommendations from the Medical Board of the National Psoriasis Foundation. Full Text available with Trip Pro

Psoriasis in Solid Organ Transplant Patients: Best Practice Recommendations from the Medical Board of the National Psoriasis Foundation. Treatment of solid organ transplant patients who have psoriasis can be a therapeutic challenge. Biologic and systemic drugs used to treat psoriasis can result in an increase in infections or malignancies.We sought to develop a treatment algorithm for organ transplant recipients (OTR) diagnosed with psoriasis vulgaris.A systematic literature search (...) for psoriasis treatment in organ transplant patients was performed using MEDLINE and GOOGLE.In mild-to-moderate disease, topical therapy should be a first-line treatment. In moderate-to-severe disease, first-line treatment is acitretin with narrow band ultraviolet light (NBUVB), NBUVB, or acitretin. Second-line treatment is increasing the current antirejection drug dose. Other systemic or biologic therapies should be reserved for more severe or refractory cases.No systematic clinical studies have been done

2017 Journal of Dermatological Treatment

182. Evaluation of psoriasis severity and inflammatory responses under concomitant treatment with methotrexate plus micronutrients for psoriasis vulgaris: a randomized double blind trial. (Abstract)

Evaluation of psoriasis severity and inflammatory responses under concomitant treatment with methotrexate plus micronutrients for psoriasis vulgaris: a randomized double blind trial. We evaluated the effectiveness of concomitant treatment with methotrexate (MTX) plus micronutrients in comparison with monotherapy with MTX only in psoriasis patients. Plasma levels of interleukin-1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α) were also measured and their association with clinical severity (...) was evaluated.Thirty psoriasis patients 20 to 50 years old with a PASI score > 10 were divided randomly into two groups. Both groups were given oral methotrexate (0.2-0.3 mg/kg/week) for 12 weeks. In addition, Group B received one tablet of micronutrient supplement daily. Disease severity was calculated using the psoriasis area and severity index (PASI) score before and after 12 weeks. Levels of IL-1β and TNF-α were measured using enzyme-linked immunosorbent assay (ELISA).We found that 13 (86.6%) patients in Group

2017 Acta dermatovenerologica Alpina, Pannonica, et Adriatica Controlled trial quality: uncertain

183. Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. (Abstract)

Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. The emergence of new biological therapies showing high and sustained level of Psoriasis Area and Severity Index (PASI) 90 response has provided the possibility of both greater skin clearance and increased quality of life (QOL).To evaluate the association of greater response (...) . 56.7%; p < .001). IGA results were similar.These results show that PASI 90-100 is a relevant therapeutic goal in moderate to severe psoriasis compared to PASI 75-89 when considering patients' QOL.

2017 Journal of Dermatological Treatment Controlled trial quality: uncertain

184. A European subset analysis from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) shows country-specific features: Results from psoriasis patients in Spain. Full Text available with Trip Pro

A European subset analysis from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) shows country-specific features: Results from psoriasis patients in Spain. The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey data were not analysed to account for cultural and healthcare system differences across European countries (EC).To utilize MAPP data to characterize psoriasis in Spanish patients, including severity assessment (...) and Dermatology Life Quality Index (DLQI).The MAPP survey was conducted between June and August 2012. This analysis included 1700 patients with self-reported psoriasis (without psoriatic arthritis) from France (n = 349), Germany (n = 311), Italy (n = 359), Spain (n = 354) and the United Kingdom (n = 327).Patients from Spain vs. other EC self-reported higher mean body mass index (26.9 vs. 25.6, P ≤ 0.001), lower prevalence of depression (6% vs. 12%, P = 0.002) and higher mean self-perceived psoriasis severity

2017 Journal of the European Academy of Dermatology and Venereology

185. Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis. Full Text available with Trip Pro

Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis. Tofacitinib is an oral Janus kinase inhibitor. Efficacy and safety of tofacitinib in patients with moderate-to-severe plaque psoriasis have been demonstrated.We sought to assess the efficacy of tofacitinib for the treatment of nail psoriasis over a period of 52 weeks.In 2 identical phase 3 studies (OPT Pivotal 1 and 2), patients (...) were randomized 2:2:1 to receive tofacitinib 5 mg, tofacitinib 10 mg, or placebo, twice daily. At week 16, placebo-treated patients were re-randomized to tofacitinib. This post hoc analysis of patients with existing nail psoriasis assessed the Nail Psoriasis Severity Index (NAPSI) score and proportions of patients achieving ≥50% reduction in NAPSI from baseline (NAPSI50), NAPSI75, or NAPSI100.Baseline mean NAPSI scores for patients treated with tofacitinib 5 mg (N = 487), tofacitinib 10 mg (N = 476

2017 Journal of the American Academy of Dermatology Controlled trial quality: uncertain

186. A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer (...) to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis The safety and scientific validity of this study is the responsibility

2017 Clinical Trials

187. A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration (...) or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators

2017 Clinical Trials

188. Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups. (Abstract)

Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups. Psoriasis is a chronic inflammatory skin condition affecting diverse racial/ethnic groups throughout the world. Large population-based studies suggest that psoriasis occurs most often in individuals of European ancestry, followed by black and Hispanic individuals, although the true prevalence of psoriasis in non-white (...) individuals is likely underestimated. Despite similarities in psoriasis between ethnic groups, there are notable differences in the presentation, quality-of-life impact, and treatment of psoriasis with important implications for the management of non-white individuals. Overall, heterogeneity in psoriasis susceptibility alleles, in combination with cultural and socioeconomic factors, may explain these differences. In this article, we review the epidemiology, clinical presentation, genetic polymorphisms

2017 American journal of clinical dermatology

189. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. Full Text available with Trip Pro

Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. The effect of systemic therapy on malignancy risk among patients with psoriasis is not fully understood.Evaluate the impact of systemic treatment on malignancy risk among patients with psoriasis in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).Nested case-control analyses were performed among patients with no history of malignancy. Cases were defined as first malignancy (other (...) than nonmelanoma skin cancer) in the Psoriasis Longitudinal Assessment and Registry, and controls were matched by age, sex, geographic region, and time on registry. Study therapies included methotrexate, ustekinumab, and tumor necrosis factor-α (TNF-α) inhibitors. Exposure was defined as 1 or more doses of study therapy within 12 months of malignancy onset and further stratified by duration of therapy. Multivariate conditional logistic regression, adjusted for potential confounders, was used

2017 Journal of American Academy of Dermatology

190. Identification of PTPN22, ST6GAL1 and JAZF1 as Psoriasis Risk Genes Demonstrates Shared Pathogenesis between Psoriasis and Diabetes. (Abstract)

Identification of PTPN22, ST6GAL1 and JAZF1 as Psoriasis Risk Genes Demonstrates Shared Pathogenesis between Psoriasis and Diabetes. The biological connections between psoriasis and diabetes have been suggested by epidemiological, immunological and genetic studies. To identify additional shared susceptibility loci and investigate shared pathogenesis between these two diseases, we genotyped 89 reported diabetes susceptibility loci in 4456 psoriasis cases and 6027 controls of Chinese population (...) using the MassARRAY system from Sequenom. We discovered three significant associations at rs6679677 on 1p13.2 (P=6.15×10-5 , OR=5.07), rs16861329 on 3q27.3 (P=2.02×10-4 , OR=0.87) and rs849135 on 7p15.1 (P=6.59×10-9 , OR=1.78), which suggested PTPN22, ST6GAL1 and JAZF1 as novel susceptibility genes for psoriasis in Chinese population. Our findings implicated the involvement of T-cell receptor signalling pathway in the pathogenesis of psoriasis and further confirmed the shared genetic susceptibility

2017 Experimental Dermatology

191. Investigation of dietary supplements prevalence as complementary therapy: Comparison between hospitalized psoriasis patients and non-psoriasis patients, correlation with disease severity and quality of life. (Abstract)

Investigation of dietary supplements prevalence as complementary therapy: Comparison between hospitalized psoriasis patients and non-psoriasis patients, correlation with disease severity and quality of life. Psoriasis patients are often displeased with traditional medical treatments and they may self-prescribe dietary supplements as an alternative or complementary treatments. We aimed to investigate the prevalence of self-medication of dietary supplements among psoriasis and non-psoriasis cases (...) and its impact on disease severity and quality of life.This case-control study evaluated 252 records of psoriasis patients and 245 non-psoriasis cases. Dietary supplementation over last 30days and characteristics, including age, age at onset of disease, co-morbidities, smoking and education were recorded. Psoriasis area and severity index (PASI) and dermatology quality of life index (DLQI) were calculated. P value less than 0.05 was considered as significant level.This study consisted 138 psoriasis

2017 Complementary Therapies In Medicine

192. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. (Abstract)

Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. The Australasian Psoriasis Collaboration has reviewed the evidence for managing moderate to severe psoriasis in those who are pregnant or are breast-feeding, or planning a family. The severity of the psoriasis, associated comorbidities and specific anti-psoriasis treatment, along with other exposures, can have a deleterious effect on pregnancy outcomes. Psoriasis itself increases the risk (...) of preterm and low birthweight babies, along with spontaneous and induced abortions, but no specific birth defects have been otherwise demonstrated. The baseline risk for a live born baby to have a major birth defect is 3%, and significant neuro-developmental problem is 5%. In Australia, pregnant women with psoriasis are more likely to be overweight or obese, depressed, or smoke in their first trimester, and are also less likely to take prenatal vitamins or supplements. Preconception counselling

2017 Australasian Journal of Dermatology

193. Skin-infiltrating, interleukin-22-producing T cells differentiate pediatric psoriasis from adult psoriasis. (Abstract)

Skin-infiltrating, interleukin-22-producing T cells differentiate pediatric psoriasis from adult psoriasis. Evidence from adult psoriasis studies implicates an imbalance between regulatory and effector T cells, particularly TH-17-producing T cells, in the pathogenesis of psoriasis. Little is known about the immunopathology of psoriasis in children.We sought to functionally characterize the inflammatory cell profiles of psoriatic plaques from pediatric patients and compare them with healthy, age (...) -matched controls and adult psoriasis patients.Skin samples from pediatric psoriasis patients and healthy controls were analyzed by multiparameter flow cytometry to determine the dominant immune cell subsets present and cytokines produced.Lesional tissue from pediatric psoriasis patients had significantly increased interleukin (IL) 22 derived from CD4+ and CD8+ cells compared with the tissues from healthy pediatric controls and adult psoriasis patients. Tissue from pediatric psoriasis patients had

2017 Journal of American Academy of Dermatology

194. Sustained PASI, DLQI and EQ-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register. Full Text available with Trip Pro

Sustained PASI, DLQI and EQ-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register. Few studies have analysed the long-term effects of biological treatment in psoriasis. PsoReg, the Swedish national register for systemic psoriasis treatment, started in 2006 and now includes 10 years of real-world data on the effectiveness of biological treatment.To analyse the long-term real-world outcome data of patients who are biologically (...) naïve with moderate-to-severe psoriasis after switching to biological treatment.An observational study of patients who are biologically naïve with at least one registration of outcome before switching to biological treatment while included in PsoReg and at least one follow-up visit. Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI) and EuroQol-5D (EQ-5D) values were analysed at 3-5 months, 6-11 months and at least once after ≥ 1 year, up to 9 years after the switch

2017 British Journal of Dermatology

195. Guselkumab for moderate to severe psoriasis

Guselkumab for moderate to severe psoriasis Guselkumab for moderate to severe psoriasis Guselkumab for moderate to severe psoriasis NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Guselkumab for moderate to severe psoriasis. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' objectives (...) Psoriasis is a skin condition that causes the skin to look red and flaky, with crusty patches of skin covered with silvery scales. These patches of skin are often sore and cause itching. Common areas for psoriasis patches to occur are the elbows, knees, scalp and lower back. The treatment of psoriasis is often successful, but does not completely cure the condition. Psoriasis usually comes and goes so there are times when a patient who has psoriasis may feel well, but other times when the condition

2016 Health Technology Assessment (HTA) Database.

196. Tofacitinib for chronic plaque psoriasis - second line

Tofacitinib for chronic plaque psoriasis - second line Tofacitinib for chronic plaque psoriasis – second line Tofacitinib for chronic plaque psoriasis – second line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Tofacitinib for chronic plaque psoriasis – second line . Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon (...) Scanning Review. 2015 Authors' objectives Tofacitinib is intended to be used as second line therapy for the treatment of chronic moderate-to-severe plaque psoriasis. If licensed, it will provide an additional oral treatment option for this patient group. Tofacitinib is a novel janus kinase (JAK) inhibitor that inhibits JAK1, 2 and 3 in vitro, with functional specificity for JAK1 and 3. Inhibition of JAK1 and 3 blocks signalling of several cytokines which are required for lymphocyte activation

2015 Health Technology Assessment (HTA) Database.

197. Tildrakizumab for moderate to severe plaque psoriasis

Tildrakizumab for moderate to severe plaque psoriasis Tildrakizumab for moderate to severe plaque psoriasis Tildrakizumab for moderate to severe plaque psoriasis NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Tildrakizumab for moderate to severe plaque psoriasis. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon (...) Scanning Review. 2015 Authors' objectives Tildrakizumab is intended for use in patients with moderate to severe plaque psoriasis who have failed to respond to, have contraindications to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA (psoralen ultraviolet light) therapy. If licensed, it will offer an additional treatment option for these patients who have not responded to topical or systemic therapies, and offer an alternative to other biological agents

2015 Health Technology Assessment (HTA) Database.

198. Ixekizumab for moderate to severe chronic plaque psoriasis

Ixekizumab for moderate to severe chronic plaque psoriasis Ixekizumab for moderate to severe chronic plaque psoriasis Ixekizumab for moderate to severe chronic plaque psoriasis NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Ixekizumab for moderate to severe chronic plaque psoriasis. Birmingham: NIHR Horizon Scanning Research&Intelligence (...) Centre. Horizon Scanning Review. 2015 Authors' objectives Ixekizumab is intended for the treatment of moderate to severe chronic plaque psoriasis in adults who are candidates for systemic therapy. If licensed, ixekizumab will offer an additional treatment option for this patient group. Treatment with ixekizumab may result in some patients achieving near/full clearance of psoriasis symptoms. Ixekizumab is a humanised immunoglobulin G subclass 4 (IgG4) monoclonal antibody that neutralises interleukin

2015 Health Technology Assessment (HTA) Database.

199. Psoriasis

Psoriasis Psoriasis - NICE CKS Share Psoriasis: Summary Psoriasis is a systemic, immune-mediated, inflammatory skin disease which typically has a chronic relapsing-remitting course, and may have nail and joint (psoriatic arthritis) involvement. Chronic plaque psoriasis (including scalp psoriasis, flexural psoriasis, and facial psoriasis) is the most common form, affecting 80–90% of people with psoriasis. The second most common form is localized pustular psoriasis of the palms and soles. Other (...) forms of psoriasis include: Guttate psoriasis. Nail psoriasis. Erythrodermic and generalized pustular psoriasis (rare medical emergencies, may be life-threatening). Psoriasis is common, with about 1.3–2.2% of the UK population affected. Several factors are associated with the onset or exacerbation of psoriasis, including infection, drugs (including corticosteroid withdrawal), ultraviolet light exposure, trauma, hormonal changes, stress, smoking, and alcohol. Psoriasis may be associated with other

2018 NICE Clinical Knowledge Summaries

200. Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis (Abstract)

Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis To evaluate the effect of brodalumab on psoriasis signs and symptoms assessed by the Psoriasis Symptom Inventory (PSI) in patients with psoriatic arthritis (PsA).This prespecified analysis of a phase II study (NCT01516957) evaluated patients with active PsA and psoriasis-affected body surface area ≥ 3%, randomized to brodalumab (140 or 280 mg (...) ) or placebo every 2 weeks (Q2W) for 12 weeks with loading dose at Week 1. At Week 12, patients entering an open-label extension received brodalumab 280 mg Q2W. The PSI measures 8 psoriasis signs and symptoms: itch, redness, scaling, burning, stinging, cracking, flaking, and pain. PSI response is defined as total PSI ≤ 8 (range 0-32), each item ≤ 1 (range 0-4). PSI scores were assessed at weeks 12 and 24.There were 107 eligible patients. At Week 12, mean improvement in PSI scores was 7.8, 11.2, and 1.5

2016 EvidenceUpdates Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>